Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 May;43(7-8):700-4.
doi: 10.1016/j.clinbiochem.2010.01.016. Epub 2010 Feb 12.

Development and validation of a comprehensive mutation and deletion detection assay for SDHB, SDHC, and SDHD

Dragana Milosevic  1 , Patrick Lundquist, Kendall Cradic, Noemi Vidal-Folch, ThanhTruc Huynh, Karel Pacak, Stefan K G Grebe
Affiliations

Development and validation of a comprehensive mutation and deletion detection assay for SDHB, SDHC, and SDHD

Dragana Milosevic et al. Clin Biochem. 2010 May.

Abstract

Background: Lack of sequencing validation and complexity of deletion testing hinder genetic diagnosis of SDH-associated paraganglioma/pheochromocytoma.

Methods: We developed sequencing assays and multiplex ligation-dependent probe amplification (MLPA) deletion detection for SDHB, SDHC and SDHD. Clinical performance was validated on 141 blinded samples, previously tested at NIH.

Results: Sequencing and deletion detection were highly reproducible and agreed with previous NIH results in 99.3% and 100%, respectively.

Conclusions: DNA sequencing combined with MLPA allows reliable and simplified genotyping of SDHB, SDHC and SDHD.

PubMed Disclaimer

Figures

Figure 1
Figure 1. MLPA deletion detection
The top half of the figure depicts the signals of a patient sample (blue peaks) compared to multi-run averaged female control signals (red peaks). The bottom half of the figure shows the peak ratios of averaged control signal to the signal generated in a run by control samples (male, left upper and female, right upper) and the response ratios observed in the sample of a male patient with a complete deletion of the SDHB gene (left lower) and a male patient with a deletion of exon 1 of SDHB. The horizontal green lines and the green shaded area on each graph indicate the expected normal range for the signal ratios. Of note is the difference between both normal control and patient sample with regards to the signal ratio of the DMD control gene. The DMD gene is located on the X-chromosome and is therefore only present in a single copy in male patients, thus serving as a convenient control gene for the expected deviation of a heterozygous deletion from the established normal signal ratio range.
Figure 2
Figure 2. Decision tree and workflow for SDH genotyping
The flow chart depicts a suggested decision tree and workflow for SDH genotyping in patients with suspected or known familial paraganglioma (PGL) or pheochromocytoma (PC). This includes most patients with PGL. With regards to PC, activating mutations in RET, and inactivating mutations or deletions in VHL and NF1 also have to be considered in suspected familial cases, and this is indicated at the top of the decision tree. However, an in-depth discussion and depiction of workflow for all familial variants of chromaffin tumors is beyond the scope of this article and the figure concentrates on the SDH genotyping.
See this image and copyright information in PMC

References

    1. Timmers HJLM, Gimenez-Roqueplo AP, Mannelli M, Pacak K. Clinical Aspects of SDHx-related pheochromocytoma and paraganglioma. Endocrine-Related Cancer. 2009;16:391–400. - PMC - PubMed
    1. Lima J, Feijao T, da Silva AF, Pereira-Castro I, Fernandez-Ballester G, Maximo V, Herrero A, Serrano L, Sobrinho-Simones M, Garcia-Rostan G. High frequency of germline Succinate Dehydrogenase mutations in sporadic cervical paraganglioma in Northern Spain; Mitochondrial Succinate dehydrogenase structure-function relationships and clinical-pathological correlations. The Journal of Clinical Endocrinology and Metabolism. 2007;92(12):4853–4864. - PubMed
    1. Bryant J, Farmer J, Kessler LJ, Townsend RR, Nathanson KL. Pheochromocytoma: The expanding Genetic Differential Diagnosis. Journal of the National Cancer Institute. 2003;95(16) - PubMed
    1. Gimenez-Roqueplo AP, Favier J, Rustin P, Rieubland C, Crespin M, Nau V, Khau Van Kien P, Corvol P, Plouin PF, Jeunemaitre X. Mutations in the SDHB gene are associated with extra- adrenal and/or malignant pheochromocytoma. Cancer Research. 2003;63:5615–5621. - PubMed
    1. Eisenhofer G, Bornstein SR, Brouwers FM, Cheung Nai-Kong V, Dahia PL, de Krijger RR, Giordano TJ, Greene LA, Goldstein DS, Lehnert H, Manger WM, Maris JM, Neumann HPH, Pacak K, Shulkin BL, Smith DI, Tischler AS, Young WF., jr Malignant pheochromocytoma: current status and initiatives for future progress. Endocrine – Related Cancer. 2004;11:423–436. - PubMed

MeSH terms

LinkOut - more resources